Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa-associated refractory pruritus (Abstract)

Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa-associated refractory pruritus Case Reports; JAAD Case Rep 19 June 2023 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339115/ A rare subtype of epidermolysis bullosa, epidermolysis bullosa pruriginosa (EBP) is characterized by severely pruritic lichenified and hypertrophic prurigo-like nodules and plaques secondary to chronic itching. No standard first-line therapy currently exists. Reported is a case of […]

Low-Dose Naltrexone in Rheumatological Diseases (Abstract)

Low-Dose Naltrexone in Rheumatological Diseases Mediterr J Rheumatol 31 March 2023 https://pubmed.ncbi.nlm.nih.gov/37223594/ Background: Naltrexone has been approved for alcohol and opioid abuse by the FDA. At low-dose naltrexone (LDN) has been used in several diseases including chronic pain and autoimmune conditions, including rheumatic disorders. Aim: To review the use of LDN in rheumatic diseases: systemic […]

LDN Webinar 18 May 2022 (LDN; low dose naltrexone)

  LDN Webinar 18 May 2022 (LDN; low dose naltrexone) LDN Questions Answered Live by Pharmacist Dr Masoud Rashidi – LDN Specialist Dr Sato-Re Dr Mathewson Sponsored by Innovative Compounding Pharmacy icpfolsom.com